NEW YORK (GenomeWeb) – WaveSense, a company developing a platform for rare cell isolation and enrichment, said today that it has received CE-IVD marking for its technologies.

The approval includes the company's EpiSep direct-to-slide cell enrichment technology, as well as its proprietary paramagnetic bead technology, which allows for selective isolation of cells that express CD138.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

CNN reports that researchers have tied a new variant to opioid addiction risk.

Organoids derived from patients' tumors may help determine what chemotherapy treatment patients would benefit from, according to New Scientist.

An initiative from GenomeAsia 100K hopes to increase the number of South Asians in genetic research, according to NBC News.

In Science this week: genomic analysis of ancient and modern horses indicates population turnover, and more.